Details of the Drug Reposition

General Information of This Drug (ID: DMMPTLH)

• Drug Name: Entrectinib (DMMPTLH)
• Synonyms: 1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

1 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Non-small-cell lung cancer	DISI0V1B	2C25	Approved	[1]

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Solid tumour/cancer	DISZR48F	2A00-2F9Z	Phase 2	[2]
Colorectal cancer	DISNH7P9	2B91.Z	Phase 2	[3]

2 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Mammary analogue secretory carcinoma	DISGXZ2Q	2C60	Phase 1	[4]
Neuroblastoma	DISVZBI4	2D11.2	Phase 1	[3]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] ClinicalTrials.gov (NCT04589845) Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372... Cancer Discov. 2017 Apr;7(4):400-409.